Quarterly ResultMay 6, 2026, 04:20 PM
Edwards Lifesciences Q1 Net Sales $1.65B; EPS $0.66
AI Summary
Edwards Lifesciences reported a strong increase in net sales and net income for the first quarter of 2026, with sales reaching $1,648.6 million and diluted EPS at $0.66. However, the company recognized a significant $123.6 million loss on impairment of investments and experienced a substantial decrease in net cash provided by operating activities. The quarter also included the acquisition of Autus Valve Technologies for $128.9 million, which resulted in a $65.2 million gain on remeasurement of a previously held interest.
Key Highlights
- Net sales increased 16.7% to $1,648.6 million for Q1 2026.
- Net income attributable to Edwards Lifesciences rose to $380.7 million.
- Diluted earnings per share (EPS) was $0.66, up from $0.61 year-over-year.
- Recognized a $123.6 million loss on impairment of investments.
- Acquired Autus Valve Technologies for $128.9 million, recording a $65.2 million gain.
- Net cash provided by operating activities decreased to $43.8 million.
- Purchased $421.8 million of treasury stock during the quarter.